Blog, News and Events

11 March 2026

Exploring the Human Lipoprotein Profile of PXB-mice and PXB-cells

Lipids are important biomolecules that contribute to homeostasis. They can act as energy reserves, are used structurally, and play an important role in metabolic processes including drug metabolism. Lipids complex with proteins resulting in a lipoprotein particle that enables the hydrophobic lipids to be transported throughout the body via the blood stream. Changes in the lipoprotein/lipid profile are associated with diseases such as metabolic dysfunction-associated fatty liver disease (MAFLD), atherosclerosis, hypothyroidism, and cardiovascular disease as well as some genetic disorders. As such, therapeutics are being developed to target dyslipidemia.

PXB-mouse, Blog, PXB-cells

27 February 2026

Translational liver disease models designed to suit your research needs

At PhoenixBio, we strive to help improve human health through the broad application of our humanized liver chimeric mouse model, the PXB-mouse. Our chimeric mouse model has a highly humanized liver, with human-specific metabolism pathways and gene expression as well as human-like lipid profiles, making this a relevant model for drug discovery and development projects. While we commercially produce PXB-mice using a single human hepatocyte donor lot, we understand that some research may require different hepatocyte donors, such as donors with specific characteristics (HLA typing or disease state) or even donors from different species (NHPs, humans, or others). Therefore, we offer custom transplantation services with our host mouse (cDNA-uPA/SCID background) which allows researchers to select and test engraftment of a hepatocyte donor that meet their specific research needs. First, we will highlight research that used a hepatocyte donor transplanted by our expert team into host animals for a rare genetic disease, Ornithine Transcarbamylase Deficiency (OTCD).

PXB-mouse, Blog

19 August 2025

Advancing the Development of Safe & Effective LNP-Delivered Therapies using Humanized Liver Models

Oligonucleotide therapeutics have shown promise as a diverse treatment option for a wide range of diseases. Developing successful oligonucleotide therapeutics depends on being able to efficiently deliver the therapeutic to the target cells.

PXB-mouse, Blog

18 August 2025

Bridging the translational gap: Humanized Liver models as predictive tools for RNA therapeutic success

The field of RNA therapeutics, with its potential for treating a wide range of diseases, continues to experience rapid growth and attracts significant investment. According to the American Society of Gene & Cell Therapy (ASGCT), as of Q1 2025, 35 RNA therapies have been approved globally and another 1,298 are currently in development (between preclinical and pre-registration stages) [1].

PXB-mouse, Blog

19 December 2024

Humanized Liver Models: Revolutionizing RNA Therapeutic Development

The rapid growth of RNA therapeutics, including siRNA and mRNA, is transforming the pharmaceutical and medical landscape, offering unprecedented potential for treating diseases ranging from viral infections to metabolic disorders. Despite this promise, translating these groundbreaking treatments from the lab to the clinic is fraught with challenges.

PXB-mouse, News, Blog

2 May 2024

Increasing translational potential with PXB-mice as an alternative to non-human primates

Non-human primates (NHPs) share a wide range of genetic and physiological features in common with humans. Yet, despite their widespread use in preclinical research, NHP models suffer from several limitations that can lead to a lack of translatability in clinical trials.

PXB-mouse, Blog

21 August 2023

PXB-mouse: Overcoming species-to-species differences to accurately predict hepatotoxicity in therapeutic development

It is estimated that 40% of drug candidates have failed to make it to market because of toxicity.¹ One of the most common adverse drug reactions is drug-induced liver injury (DILI), whereby patients experience acute illness, often with symptoms similar to hepatitis and cholestasis. Today, DILI is the leading cause of drug candidate failure and post-market withdrawals.² The high incidence of DILI in clinical trials, and even post-market events, is partly due to the use of conventional animal models at preclinical stages. Conventional models are notoriously poor predictors of efficacy and toxicity in the liver, due to species-to-species variation. In contrast, the PXB-mouse® model, with its humanized liver, provides a highly predictive model of human physiology and human-specific hepatotoxicity, allowing for more accurate prediction of human outcomes, and, therefore, aiding the smooth progression of new therapeutics into the clinic.

PXB-mouse, Blog

7 August 2023

Setting up HBV studies for human translational success

Hepatitis B is a serious and globally prevalent disease with 296 million people worldwide living with chronic hepatitis B virus (HBV) infections. Recent advances in HBV therapeutics have made infection a treatable disease, but they only disrupt certain areas of the HBV lifecycle. As a result, if the therapeutics are withdrawn, patients can relapse. What’s more, long-term use can cause antiviral resistance. To cure the disease, therapeutics need to address every stage of the HBV lifecycle, providing both seroclearance of the hepatitis B surface antigen (HBsAg) and silencing of the genomically integrated HBV DNA. However, investment in this space carries considerable risk as developers struggle to move treatments from animal models to human studies. Notably, human responses to HBV therapies are notoriously difficult to predict and traditional animal models translate poorly to the human environment, causing significant delays, as well as safety, cost, and efficacy concerns.

PXB-mouse, Blog